Investigators: Karen Anderson, M.D., Ph.D and Garrick Wallstrom, Ph.D..
Collaborators: Elizabeth Unger, M.D., Ph.D. (CDC, Chronic Viral Disease Branch), Erich Sturgis, M.D. (The University of Texas MD Anderson Cancer Center), Jon Mork, M.D. (Oslo University Hospital, Norway), Robert Haddad, M.D. (Dana Farber Cancer Institute), Gypsyamber D'Souza, Ph.D. (Johns Hopkins University), Marshall Posner, M.D. (Mount Sinai School of Medicine), and Neil Gross, M.D., F.A.C.S. (Oregon Health and Science University)
|Who gets it?
What are the symptoms?
|How do we detect it now?
How is it currently treated?
|What are the current challenges?|
OPC can affect young adults to the elderly
Cervical cancer can affect all women
There is evidence that patients with OPC and Cervical cancer have immune system changes compared to healthy individuals. Our goal is to find these differences and use them to discover and validate biomarkers for detection and disease prognosis, and to personalize its treatment. Currently, we are using programmable magnetic bead arrays that contain HPV-viral proteins to identify antibodies in the blood of OPC and Cervical cancer patients. Antibodies that bind to the HPV-proteins can be detected by fluorescence and by comparing results from patients to those of healthy people, biomarkers can be validated.
In addition to identifying biomarkers for early detection of head and neck cancer caused by HPV-infection, we are also investigating whether the HPV vaccine used to prevent cervical cancer in girls also protects against head and neck cancer.
For more details, visit Dr. Karen Anderson's website.